GlaxoSmithKline confirms multi-million investment for Worthing manufacturing base

News Posted 12/12/13
Major drugs company pledges significant investment in key West Sussex site

A £25 million investment into plant manufacturing facilities at GlaxoSmithKline in Worthing has been greeted as vital boost for the area’s economy.

The project, which is part of a national drive by the global drug manufacturer totaling £200 million to improve several key sites within its portfolio, has ensured 950 jobs at its West-Sussex location will be maintained.

As part of the investment, upgrades at the site will include the construction of a new bulk sterile building and filling line for its AugmentinTM antibiotic.

The move has been assisted with the company making use of Patent Box taxation laws, which offer favourable investment incentives to high-tech and science-based businesses.

Bryan Turner, Worthing Borough Council cabinet member for regeneration believed the investment in West Sussex was a strong marker of confidence in the area’s economy.

He said: “The £25 million that Glaxo is investing in its Worthing site at Broadwater is good news for the area’s economy. “I worked for the company when I first came to the area, when it was formerly Beechams. We were talking about how the site was in need of investment 33 years ago and now it is finally happening.

“This announcement will mean that the 950 jobs there will be secure, with the funding going towards production of two important antibiotic drugs- Augmentin and Bactroban. “It shows that the company, which has a wide global reach, is committed to staying in Worthing.”

Roger Connor, GSK president of global manufacturing hailed the millions being poured into the site, and further funding towards another of its bases in Ware, Hertfordshire, as significant in the company’s development.

He said: “The investments announced today are in addition to that and will allow us to harness new technologies that have the potential to deliver a step-change in how we make medicines. These new technologies could significantly reduce costs, improve quality and enable the manufacture of medicines in weeks rather than years and I am delighted that we have been able to bring these investments to the UK.”

pic: Glaxo headquarters in Brentford

Tweets from @SEBmagazine